Paget's disease of the breast differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 45: Line 45:
*[[Malignant]]
*[[Malignant]]
| align="left" style="background:#F5F5F5;" |Most the patients have underlying [[Breast cancer|breast cancer.]]
| align="left" style="background:#F5F5F5;" |Most the patients have underlying [[Breast cancer|breast cancer.]]
| align="left" style="background:#F5F5F5;" |Ulcerated, crusted, or scaling lesion on the [[nipple]] that extends to the [[areolar region]]  
| align="left" style="background:#F5F5F5;" |
* Ulcerated, crusted, or scaling lesion on the [[nipple]] that extends to the [[Areola|areolar region]].
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 52: Line 53:
* Well-demarcated [[erythematous]] and [[Desquamation|desquamative plaques]] with irregular borders seen.
* Well-demarcated [[erythematous]] and [[Desquamation|desquamative plaques]] with irregular borders seen.
* [[Breast lump]] palpated in >50% cases.
* [[Breast lump]] palpated in >50% cases.
| align="left" style="background:#F5F5F5;" |Usually unilateral nipple is effected
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* The Paget cells are large round [[cells]] with abundant clear [[cytoplasm]] and [[atypical nuclei]].  
* Usually unilateral [[nipple]] is effected
| align="left" style="background:#F5F5F5;" |
* The Paget cells are large round [[cells]] with abundant clear [[cytoplasm]] and [[Nuclei|atypical nuclei]].  
* The cytoplasm is often [[Periodic acid-Schiff|periodic-acid-Schiff (PAS)]] positive
* The cytoplasm is often [[Periodic acid-Schiff|periodic-acid-Schiff (PAS)]] positive
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
Line 60: Line 62:
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* 90% of the cases  will have an invasive [[Ductal carcinoma|intraductal carcinoma of the breast]].
* 90% of the cases  will have an invasive [[Ductal carcinoma|intraductal carcinoma of the breast]].
* May positive staining against [[CEA antigen]]  and the c erbB-2 / her-2 neu oncoprotein.
* May positive staining against [[CEA antigen]]  and the c erbB-2 / her-2 neu [[Oncogene|oncoprotein]].
* Prognosis is worse in men.
* [[Prognosis]] is worse in men.
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Atopic dermatitis]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Atopic dermatitis]]
Line 68: Line 70:
* [[Benign]]
* [[Benign]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Epidermal barrier dysfunction
* [[Epidermal]] barrier dysfunction
* [[Immune]] dysregulation
* [[Immune]] dysregulation
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
Line 107: Line 109:
* [[Family history]] of  [[atopy]]
* [[Family history]] of  [[atopy]]
* History of [[Breast implants|silicon implants]] or [[Breast reconstruction|reconstruction]] of nipple areola complex or [[lactation]].
* History of [[Breast implants|silicon implants]] or [[Breast reconstruction|reconstruction]] of nipple areola complex or [[lactation]].
* Personal history of [[atopy]] or [[extramammary Paget's disease]] or [[hematological diseases]]
* Personal history of [[atopy]] or [[extramammary Paget's disease]] or hematological [[diseases]]
* Combined usage of [[interferon alfa-2b]] and [[ribavirin]].
* Combined usage of [[interferon alfa-2b]] and [[ribavirin]].
|-
|-
Line 113: Line 115:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Benign]]
* [[Benign]]
* Neoplasm of breast lactiferous ducts
* [[Neoplasm]] of [[breast]] [[Lactiferous duct|lactiferous ducts]].
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Proliferation]] of the inner  [[Epithelial|epithelial layer]] and outer, [[basal layer]] of [[myoepithelial cells]] of the [[Lactiferous duct|lactiferous ducts]]  the [[nipple]].
* [[Proliferation]] of the inner  [[Epithelial|epithelial layer]] and outer, [[basal layer]] of [[myoepithelial cells]] of the [[Lactiferous duct|lactiferous ducts]]  the [[nipple]].
| align="left" style="background:#F5F5F5;" |[[Eczema]], crusts or erosion of nipple
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |Serous or bloody [[nipple discharge]].
* [[Eczema]], crusts or erosion of nipple
| align="left" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
Line 137: Line 140:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref>
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |[[Benign]]
| align="left" style="background:#F5F5F5;" |
* [[Benign]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Delayed-type [[hypersensitivity]] response
* Delayed-type [[hypersensitivity]] response
* Skin [[inflammation]] mediated by [[Haptens|hapten]]-specific T cells
* Skin [[inflammation]] mediated by [[Haptens|hapten]]-specific T cells
| align="left" style="background:#F5F5F5;" | Erythematous well-demarcated [[papules]]
| align="left" style="background:#F5F5F5;" |
* Erythematous well-demarcated [[papules]]
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
Line 151: Line 156:
* [[Lichenification|Lichenified]] [[Itch|pruritic]] [[plaques]]
* [[Lichenification|Lichenified]] [[Itch|pruritic]] [[plaques]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Eosinophilic]] spongiosis and [[microvesicles]]
* [[Eosinophilic]] [[Spongiosum|spongiosis]] and [[microvesicles]]
* [[Exocytosis]] of [[eosinophils]] and [[lymphocytes]]  
* [[Exocytosis]] of [[eosinophils]] and [[lymphocytes]]  
* Chronic - [[Hyperkeratosis]] and [[parakeratosis]]
* Chronic - [[Hyperkeratosis]] and [[parakeratosis]]
Line 175: Line 180:
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Epidermal]] [[hyperplasia]]
* [[Epidermal]] [[hyperplasia]]
* Parakeratosis
* [[Parakeratosis]]
* [[Neutrophils]] microabscesses (Munro microabscesses)
* [[Neutrophils]] microabscesses (Munro microabscesses)
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
Line 182: Line 187:
|Risk factors include
|Risk factors include
* [[Smoking]]
* [[Smoking]]
* Skin trauma
* [[Skin]] trauma
* [[Alcohol abuse]]
* [[Alcohol abuse]]
* [[Stress]]
* [[Stress]]
* Cold weather
* Cold weather
* Vitamin D deficiency  
* [[Vitamin D deficiency]]
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Melanoma|Malignant melanoma]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Melanoma|Malignant melanoma]]
Line 194: Line 199:
* Development begins with disruption of [[nevus]] growth control
* Development begins with disruption of [[nevus]] growth control
* Progression involves [[MAPK/ERK pathway]]
* Progression involves [[MAPK/ERK pathway]]
* [[RAS|N-RAS]] or [[BRAF]] [[oncogene]]<nowiki/>also involved
* [[RAS|N-RAS]] or [[BRAF]] [[oncogene]]<nowiki/> also involved.
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Macule
* [[Macule]]
* Plaque with irregular border
* [[Plaque]] with irregular border
* Variable size
* Variable size


Line 217: Line 222:
* Diameter >6 mm
* Diameter >6 mm
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Nests of  atypical melanocytes with asymmetry, poor circumscription of varying sizes and shapes
* Nests of  atypical [[melanocytes]] with asymmetry, poor circumscription of varying sizes and shapes
* Present in the lower epidermis and dermis
* Present in the lower [[epidermis]] and [[dermis]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Complete full-thickness excisional [[biopsy]] of suspicious lesions with 1 to 3 mm margin of normal skin.
* Complete full-thickness excisional [[biopsy]] of suspicious [[lesions]] with 1 to 3 mm margin of normal [[skin]].
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Ultraviolet|UV radiations]]
* [[Ultraviolet|UV radiations]]
Line 239: Line 244:
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Erythema|Erythematous]]
* [[Erythema|Erythematous]]
* Skin colored
* Coloured [[skin]]
* Patch
* Patch
* Plaque
* [[Plaque]]
* Scaly
* Scaly
* variable size
* Vsize
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 249: Line 254:
| align="center" style="background:#F5F5F5;" |N/A
| align="center" style="background:#F5F5F5;" |N/A
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Presence of dotted and/or glomerular vessels
* Presence of dotted and/or [[glomerular]] [[vessels]]
* White to yellowish surface scales
* White to yellowish surface scales
* Red-yellowish background
* Red-yellowish background
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Keratinocytic dysplasia of the
* [[Keratinocyte|Keratinocytic]] [[dysplasia]] 
*  
*  
* No infiltration into dermis
* No infiltration into [[dermis]]


* Pleomorphic keratinocytes
* [[Pleomorphic]] [[keratinocytes]]
* Hyperchromatic nuclei
* [[Hyperchromatic]] [[nuclei]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Clinical examination
* Clinical examination
Line 269: Line 274:
| align="left" style="background:#F5F5F5;" |[[Malignant]]
| align="left" style="background:#F5F5F5;" |[[Malignant]]
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* UV light induces inflammation of the skin.
* [[Ultraviolet|UV]] light induces [[inflammation]] of the [[skin]].
* Patched 1 (PTCH1) tumor suppressor gene on chromosome 9  
* Patched 1 (PTCH1) [[tumor suppressor gene]] on [[chromosome 9]]
* [[P53]] mutations.
* [[P53]] mutations.
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 280: Line 285:
| align="center" style="background:#F5F5F5;" |N/A
| align="center" style="background:#F5F5F5;" |N/A
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Superficial fine telangiectasia
* Superficial fine [[telangiectasia]]
* Shiny white to red, translucent or opaque structureless areas
* Shiny white to red, translucent or opaque structureless areas
* Multiple small erosions
* Multiple small [[erosions]].
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Large, hyperchromatic, oval nuclei
* Large, hyperchromatic, oval [[nuclei]]
* Minimal cytoplasm
* Minimal [[cytoplasm]]
* Small basaloid nodules
* Small basaloid [[nodules]].
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Biopsy]]
* [[Biopsy]]
Line 311: Line 316:
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Squamous epithelium]] extending beyond the normal transition point within the [[Duct carcinoma|duct]] orifice into ductal [[epithelium]].
* [[Squamous epithelium]] extending beyond the normal transition point within the [[Duct carcinoma|duct]] orifice into ductal [[epithelium]].
* [[Keratin]] debris can extend into duct spaces.  
* [[Keratin]] debris can extend into [[duct]] spaces.  
* [[Squamous metaplasia]] of the deep [[ducts]] filled with [[keratin]] debris can be seen along with areas of rupture and spillage of [[keratin]] into the surrounding [[stroma]].
* [[Squamous metaplasia]] of the deep [[ducts]] filled with [[keratin]] debris can be seen along with areas of rupture and spillage of [[keratin]] into the surrounding [[stroma]].
| align="left" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |

Revision as of 15:33, 27 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]

Overview

Paget's disease of the breast must be differentiated from atopic dermatitis, eczema, psoriasis, malignant melanoma, Bowen's disease, basal cell carcinoma, and pagetoid dyskeratosis.[1][2]

Differential Diagnosis

Paget’s disease of the breast must be differentiated from other benign and malignant processes of nipple-areola complex such as:

Paget's disease of the breast is often misdiagnosed as nipple eczema

Diseases Benign or Malignant Etiology Clinical manifestations Histopathology Gold Standard Associated factors
Symptoms Physical examination
Rash Nipple Discharge Erythema Mastalgia Breast Exam Other
Paget's disease of the breast[1][2] Most the patients have underlying breast cancer. + + ±
  • Usually unilateral nipple is effected
Atopic dermatitis

(Eczema)[3][4]

N/A
  • Clinical examination
Erosive adenomatosis of the nipple[5][6]
  • Eczema, crusts or erosion of nipple
+ + Biopsy: Shows absence of cytological atypia
Allergic contact dermatitis[7]
  • Erythematous well-demarcated papules
+ N/A
Psoriasis[8][9] Benign Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales + + N/A Auspitz's sign (pinpoint bleeding) Risk factors include
Malignant melanoma Malignant
  • A lesion with ABCD
    • Asymmetry
    • Border irregularity
    • Color variation
    • Diameterchanges
  • Bleeding from the lesion
± N/A
  • Pigmented lesion with:
  • Asymmetry
  • Irregular borders
  • Variegated color
  • Diameter >6 mm
  • Nests of atypical melanocytes with asymmetry, poor circumscription of varying sizes and shapes
  • Present in the lower epidermis and dermis
  • Complete full-thickness excisional biopsy of suspicious lesions with 1 to 3 mm margin of normal skin.
Bowen’s disease Benign can turn malignant + N/A
  • Presence of dotted and/or glomerular vessels
  • White to yellowish surface scales
  • Red-yellowish background
  • Clinical examination
  • Slow growth over the years
Superficial basal cell carcinoma[10][11] Malignant + N/A
  • Superficial fine telangiectasia
  • Shiny white to red, translucent or opaque structureless areas
  • Multiple small erosions.
  • Higher incidence in men
Squamous metaplasia of lactiferous ducts (SMOLD)/ Zuska's disease[12][13] Benign + +
Lactiferous duct ectasia / Plasma cell mastitis / Comedomastitis Nipple retraction + Thick nipple discharge. Ultrasound:
Nipple Adenoma / Papillary adenoma of the nipple ± +
  • Multiple small palpable masses below
  • Usually unilateral nipple is effected
Nevoid hyperkeratosis of the nipple and areola (NHNA) [14][15] Slow growing bluish-brown verrucous thickening of the nipple or areola.
  • Usually bilateral nipple is effected
Biopsy
Benign Toker cell hyperplasia
  • Normal components of the nipple skin
  • Appears similar to paget cells.
Normal nipple- areolar complex Normal breast examination. N/A
  • Toker cells have bland nuclei and abundant eosinophilic or clear cytoplasm. Occasional clusters or glands may be present.
  • Do not generally have cellular atypia and have minimal nuclear pleomorphism.
  • Toker cells are immunoreactive for cytokeratin 7 and CAM5.2 but are not positive for HER2- neu.
Breast abscess
  • Complication of lactational mastitis in 14% of cases
  • Common among African-American women, heavy smokers and obese patients.
± + +
  • Associated symptoms of fever, nausea, vomiting.
  • Resolve after drainage/antibiotic therapy.

Ultrasound:

  • Fluid collection
  • Smoking history
  • If not lactating, patient may be diabetic.
  • History of privious breast infection
Mondors disease[16][17] Superficial phlebitis and periphlebitis of the superficial vein. Red linear cord running from the lateral margin of the breast attached to the overlying skin. + +
  • Red tender cord which may last up to 4-8 weeks before spontaneously remitting leaving a puckered groove along the breast.
  • N/A–
  • Predominantly seen in middle-aged women but is also seen in men.
  • May indicate breast cancer.
Mastitis[18][19]
  • Localized erythema, warmth, swelling, and pain.
± + ±
  • Associated symptoms of fever, chills, or rigor may be present.
  • Resolve after drainage/antibiotic therapy

Breast parenchymainflammation:

Ultrasound:

  • Ill-defined area with hyperechogenicity with inflamed fat lobules
  • Skin thickening.
History of lactation including difficulty in breastfeeding, breast engorgement, or erosion of nipples.
Inflammatory Breast Cancer[20][21] Malignant Cancer cells block the lymphatic vessels in skin covering the breast
  • Localized erythema, warmth, swelling, and pain.
+ +
  • Usually unilateral
Core needle Biopsy

References

  1. 1.0 1.1 Gaspari, Eleonora; Ricci, Aurora; Liberto, Valeria; Scarano, Angela Lia; Fornari, Maria; Simonetti, Giovanni (2013). "An Unusual Case of Mammary Paget's Disease Diagnosed Using Dynamic Contrast-Enhanced MRI". Case Reports in Radiology. 2013: 1–5. doi:10.1155/2013/206235. ISSN 2090-6862.
  2. 2.0 2.1 Lopes Filho, Lauro Lourival; Lopes, Ione Maria Ribeiro Soares; Lopes, Lauro Rodolpho Soares; Enokihara, Milvia M. S. S.; Michalany, Alexandre Osores; Matsunaga, Nobuo (2015). "Mammary and extramammary Paget's disease". Anais Brasileiros de Dermatologia. 90 (2): 225–231. doi:10.1590/abd1806-4841.20153189. ISSN 1806-4841.
  3. Song HS, Jung SE, Kim YC, Lee ES (April 2015). "Nipple eczema, an indicative manifestation of atopic dermatitis? A clinical, histological, and immunohistochemical study". Am J Dermatopathol. 37 (4): 284–8. doi:10.1097/DAD.0000000000000195. PMID 25079201.
  4. Barankin B, Gross MS (2004). "Nipple and areolar eczema in the breastfeeding woman". J Cutan Med Surg. 8 (2): 126–30. doi:10.1177/120347540400800209. PMID 15129318.
  5. Kumar PK, Thomas J (July 2013). "Erosive adenomatosis of the nipple masquerading as Paget's disease". Indian Dermatol Online J. 4 (3): 239–40. doi:10.4103/2229-5178.115534. PMC 3752489. PMID 23984247.
  6. Lewis HM, Ovitz ML, Golitz LE (October 1976). "Erosive adenomatosis of the nipple". Arch Dermatol. 112 (10): 1427–8. PMID 962337.
  7. Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
  8. Ljosaa TM, Rustoen T, Mörk C, Stubhaug A, Miaskowski C, Paul SM, Wahl AK (2010). "Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics". Acta Derm. Venereol. 90 (1): 39–45. doi:10.2340/00015555-0764. PMID 20107724.
  9. Naldi L, Parazzini F, Brevi A, Peserico A, Veller Fornasa C, Grosso G, Rossi E, Marinaro P, Polenghi MM, Finzi A (September 1992). "Family history, smoking habits, alcohol consumption and risk of psoriasis". Br. J. Dermatol. 127 (3): 212–7. PMID 1390163.
  10. Yamamoto H, Ito Y, Hayashi T, Urano N, Kato T, Kimura Y, Tanigawa T, Endo W, Kurokawa E, Kikkawa N, Taniguchi H (2001). "A case of basal cell carcinoma of the nipple and areola with intraductal spread". Breast Cancer. 8 (3): 229–33. PMID 11668245.
  11. Ulanja MB, Taha ME, Al-Mashhadani AA, Al-Tekreeti MM, Elliot C, Ambika S (2018). "Basal Cell Carcinoma of the Female Breast Masquerading as Invasive Primary Breast Carcinoma: An Uncommon Presentation Site". Case Rep Oncol Med. 2018: 5302185. doi:10.1155/2018/5302185. PMC 6051126. PMID 30057838.
  12. Gollapalli V, Liao J, Dudakovic A, Sugg SL, Scott-Conner CE, Weigel RJ (July 2010). "Risk factors for development and recurrence of primary breast abscesses". J. Am. Coll. Surg. 211 (1): 41–8. doi:10.1016/j.jamcollsurg.2010.04.007. PMID 20610247.
  13. Meguid MM, Oler A, Numann PJ, Khan S (October 1995). "Pathogenesis-based treatment of recurring subareolar breast abscesses". Surgery. 118 (4): 775–82. PMID 7570336.
  14. Mazzella C, Costa C, Fabbrocini G, Marangi GF, Russo D, Merolla F, Scalvenzi M (November 2016). "Nevoid hyperkeratosis of the nipple mimicking a pigmented basal cell carcinoma". JAAD Case Rep. 2 (6): 500–501. doi:10.1016/j.jdcr.2016.09.007. PMC 5161776. PMID 28004028.
  15. Ghanadan A, Balighi K, Khezri S, Kamyabhesari K (September 2013). "Nevoid Hyperkeratosis of the Nipple and/or Areola: Treatment with Topical Steroid". Indian J Dermatol. 58 (5): 408. doi:10.4103/0019-5154.117347. PMC 3778809. PMID 24082214.
  16. Hokama A, Fujita J (November 2010). "Mondor disease: an unusual cause of chest pain". South. Med. J. 103 (11): 1189. doi:10.1097/SMJ.0b013e3181ecfcf3. PMID 20890261.
  17. Shetty MK, Watson AB (October 2001). "Mondor's disease of the breast: sonographic and mammographic findings". AJR Am J Roentgenol. 177 (4): 893–6. doi:10.2214/ajr.177.4.1770893. PMID 11566698.
  18. Kvist LJ, Larsson BW, Hall-Lord ML, Steen A, Schalén C (April 2008). "The role of bacteria in lactational mastitis and some considerations of the use of antibiotic treatment". Int Breastfeed J. 3: 6. doi:10.1186/1746-4358-3-6. PMC 2322959. PMID 18394188.
  19. Foxman B, D'Arcy H, Gillespie B, Bobo JK, Schwartz K (January 2002). "Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States". Am. J. Epidemiol. 155 (2): 103–14. PMID 11790672.
  20. Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, Wong YN (February 2015). "Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome". Clin. Breast Cancer. 15 (1): 1–7. doi:10.1016/j.clbc.2014.05.005. PMC 4422394. PMID 25034439.
  21. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M (March 2011). "International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment". Ann. Oncol. 22 (3): 515–23. doi:10.1093/annonc/mdq345. PMC 3105293. PMID 20603440.